Vertex, J&J to Begin New Telaprevir Study
In addition, one of the arms of the new study will see whether a "lead-in" treatment with interferon and ribavirin alone before dosing of telaprevir may improve overall cure rates.
Vertex and its partner are locked in a tight race with Schering-Plough(SGP Quote) to be the first with a new direct antiviral drug aimed at hepatitis C approved in the U.S. and Europe.- Loading Comments...
- Loading Comments...
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,246.97 | 1,093.01 | 2,151.08 | 34.82 |
Oil *
77.27
|
|
UP
20.03
|
DOWN
0.06
|
DOWN
2.98
|
DOWN
0.04
|
10 Yr
3.48%
SPDR Gold
108.39
|
|
+0.20%
|
-0.01%
|
-0.14%
|
-0.11%
|
Data delayed 20 minutes |
